MCM
HAE icon

Montibus Capital Management’s Haemonetics HAE Stock Holding History

Montibus Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		$5.23M Buy
131,169
+20,869
+19% +$876K 0.57% 79
2013
Q2 		$4.56M Buy
+110,300
New +$4.47M 0.58% 73

Other funds holding HAE

Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Montibus Capital Management's HAE Position: Q3 2013 in Review

Montibus Capital Management increased its Haemonetics (HAE) stake by 19% in Q3 2013, buying an estimated $876K and bringing the position to 131,169 shares worth $5.23M. The position accounts for 0.57% of the portfolio, ranked #79.

Montibus Capital Management first reported a position in HAE in Q2 2013 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold HAE as of Q3 2013.

  • Montibus Capital Management held 131,169 shares of Haemonetics worth $5.23M as of Q3 2013.
  • Montibus Capital Management bought 20,869 Haemonetics shares in Q3 2013, an estimated $876K.
  • Haemonetics made up 0.57% of Montibus Capital Management's portfolio in Q3 2013, its #79 holding.
  • Montibus Capital Management first reported a position in Haemonetics in Q2 2013 and has held it in 2 quarters since.
  • 192 funds tracked by Wall St. Rank held Haemonetics as of Q3 2013.

Based on Montibus Capital Management's 13F filing for Q3 2013, filed 13 Nov 2013.